Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: EPro who wrote (1961)	7/25/1999 8:00:00 PM
From: Don Dorsey	Read Replies (1) \| Respond to of 2135

If expectations are too high, does anyone have an estimate of what expectations should be? While a cure would be the best human news, the best news financially would be what Folkman has talked about, turning cancer into a manageable, chronic illness. That way patients would have to keep buying this stuff the rest of their lives. I believe that if it were Amgen instead of ENMD with As, ES, 2ME2, and Thalidomide in its pipeline Wall Street would be all over it with recommendations. Is it reasonable to expect that of the drugs I just mentioned, at least one will emerge which is as effective in some cancers as most of the other drugs on the market today? The sad truth is that it won't take very good results to meet those low standards. Is it also fair to expect that because the mechanism for treatment is on normal cells, not cancer cells, that the results will be somewhat independent of the type of cancer? At least that's what has been demonstrated so far. If so, then the potential size of the market for one of these drugs would be much larger than other cancer drugs.